111, Inc. provides emergency online items and services to support Shanghai’s fight against the Covid-19 pandemic

SHANGHAI, April 13, 2022 /PRNewswire/ — In April 2022, 111, Inc. (“111” or the “Company”) (NASDAQ: YI), one of the leading technology-based healthcare platform companies in Chinahas set up an “Anti-Epidemic Command” at the earliest opportunity to coordinate its relevant departments and staff to fully participate in the fight against the pandemic by Shanghai. As a supplier of anti-epidemic items and drugs in Shanghai, 111 has so far opened various support services, including antigen test product supplies, exclusive rapid supply channel, chronic disease drug registration, free online consultation and renewal prescriptions for chronic illnesses. The company has previously used direct transport vehicles between its Eastern China operations center based in Kunshan and Shanghaiensuring fast and secure delivery of essential items and medicines in the fight against the Covid-19 pandemic by Shanghai.

On April 7the first batch of anti-epidemic items and drugs was shipped to Shanghai from 111’s East China Operations Center in Kunshan, giving a timely boost to the ongoing fight against the pandemic. Orders were collected and collated through an exclusive 111 shopping channel, and special personnel were assigned to route them through the company’s “Anti-Epidemic Command”, thereby speeding up the order fulfillment process and ensuring the fastest delivery to the front line.

1 Pharmacy, the online pharmacy of 111, sells more than one hundred thousand medicines online, covering more than 100 diseases. As medical institutions and offline pharmacies struggle to stock up, 111’s digital healthcare platform can effectively bridge the gap.

Addressing the problem of inappropriate drug purchases faced by some patients Shanghai, 111 now provides patients who need it with “chronic disease medication registration” and other services through doctors and pharmacists, and easily assigns special staff to follow up on any urgent requests of drugs. Every effort is being made to alleviate the “drug supply shortage” resulting from the current lockdown in Shanghai.

Since 1 Clinic, the online 111 hospital, launched free online clinical services, general practitioners and medical experts in pediatrics, obstetrics and gynecology, internal medicine, surgery, dermatology, oncology and other specialties have offered online consultations, prescription refills for chronic diseases and other services for the public. Electronic prescriptions have recently increased by 20% and convenient and professional medical services are now available to many in need.

Dr. YU Gang, co-founder and executive chairman of 111, said, “Shanghai is currently facing enormous challenges due to the Covid-19 pandemic. Like a ShanghaiNew York-based digital healthcare company, we take responsibility for helping the city overcome various challenges by fully leveraging our strengths in online/offline integrated platform and smart supply chain . We will devote all our efforts to support Shanghai to win this battle.”

About 111, Inc.

111, Inc. (NASDAQ: YI) (“111” or the “Company”) is a leading technology healthcare platform company committed to digitally connecting patients to medical and healthcare services health in China. The Company provides consumers with greater access to pharmaceuticals and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its network of offline virtual pharmacies. The Company also offers online health care services through its Internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service and patient management service. Additionally, the Company’s online platform, 1 Medicine, serves as a one-stop-shop for pharmacies to source a wide selection of pharmaceutical products. With the largest network of virtual pharmacies in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omnichannel drug marketing platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and price monitoring.

For more information about 111, please visit: http://ir.111.com.cn/.

Forward-looking statements

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by the terminology such as “will”, “expect”, “anticipate”, “future”, “intend”, “plan”, “believe”, “estimate”, “target”, “confident” and similar statements. Among other things, the business outlook and management quotes in this announcement, as well as 111’s strategic and operating plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the United States Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers. , directors or employees to third parties. These statements are based on management’s current expectations and current market and operating conditions and relate to events that involve known and unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in such statements. Potential risks and uncertainties include, but are not limited to, uncertainties about the Company’s ability to comply with extensive and evolving regulatory requirements, its ability to compete effectively in the changing health and wellness market, generally be in the PRC, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its retail pharmaceutical business and wholesale, and the Company’s ability to meet the standards necessary to maintain the listing of its ADSs on the Nasdaq Global Market, including its ability to remedy any failure to meet the Nasdaq’s continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the United States Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 undertakes no obligation to update any forward-looking statements as a result of new information, future events or otherwise, unless the applicable law requires it.

SOURCE 111, Inc.

For further information: For further information: 111, Inc., Investor Relations, Email: [email protected]; 111, Inc., Media Relations, Email: [email protected]Phone: +86-021-2053 6666 (China)

SOURCE 111, Inc.

Veronica J. Snell